Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Ettl, Johannes 
Titel:
Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer. 
Abstract:
Palbociclib is the first inhibitor of the cyclin-dependent kinases (CDK) 4 and 6 to be introduced into clinical practice. Preclinical investigations led to its clinical development in advanced hormone receptor (HR)-positive breast cancer. To date, 2 significant clinical trials have been fully published. In this article, the results of these trials and their clinical relevance for the management of HR-positive advanced breast cancer are discussed. 
Zeitschriftentitel:
Breast Care 
Jahr:
2016 
Band / Volume:
11 
Heft / Issue:
Seitenangaben Beitrag:
174-6 
Sprache:
eng 
Print-ISSN:
1661-3791 
TUM Einrichtung:
Frauenklinik und Poliklinik